A mosaic-based vaccine could offer at-risk people more choice when it comes to HIV prevention.
Maryam Mahdi | | Quick Read
Antiretroviral drugs have helped transform HIV from a life-threatening infection to a manageable chronic condition – an advancement that was almost unimaginable in the early 1980s. When Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases (NIAID) at the US National Institutes of Health, first entered the field, the disease didn’t even have a name, but he recognized the potential ramifications for the global community. “In 1981, I was in the early stages of a successful career studying immune-mediated diseases when the first reports came out describing the disease that would later become known as AIDS. I recognized very early on that this was going to become a global problem, and I decided to switch my focus and begin researching this disease that did not even have a name at the time – much less a known etiology. That choice informed the entire trajectory of my career,” says Fauci, whose vast research portfolio has resulted in substantial contributions to the ways HIV/AIDS is prevented, diagnosed and treated today.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.